The factors driving therapy resistance in diffuse glioma remain poorly understood. To
identify treatment-associated cellular and genetic changes, we analyzed RNA and/or DNA …

The evolutionary processes that drive universal therapeutic resistance in adult patients with
diffuse glioma remain unclear 1 , 2 . Here we analysed temporally separated DNA-…

Ionizing radiation causes DNA damage and is a mainstay for cancer treatment, but
understanding of its genomic impact is limited. We analyzed mutational spectra following …

Glioma intratumoral heterogeneity enables adaptation to challenging microenvironments
and contributes to therapeutic resistance. We integrated 914 single-cell DNA methylomes, …

Utilization of negative checkpoint regulators ( NCR s) for cancer immunotherapy has garnered
significant interest with the completion of clinical trials demonstrating efficacy. While the …

Despite aggressive multimodal treatment, glioblastoma (GBM), a grade IV primary brain
tumor, still portends a poor prognosis with a median overall survival of 12–16 months. The …

Several immunotherapy clinical trials in recurrent glioblastoma have reported long-term
survival benefits in 10–20% of patients. Here we perform genomic analysis of tumor tissue from …

Tumor hypoxia is a negative prognostic factor that is implicated in oncogenic signal activation,
immune escape, and resistance to treatment. Identifying the mechanistic role of hypoxia in …

With the recent advent of immunotherapy, there is a critical need to understand immune cell
interactions in the tumor microenvironment in both pan-cancer and tissue-specific contexts. …

Background New precision medicine therapies are urgently required for glioblastoma (GBM).
However, to date, efforts to subtype patients based on molecular profiles have failed to …